Current Issues in Oncology Drug Development, with a Focus on Phase II Trials

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.19, Iss.3, 2009-05, pp. : 556-562

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials

By Su Zheng

Clinical Drug Investigation, Vol. 30, Iss. 6, 2010-06 ,pp. : 397-403

Adis International

Access to resources Recommend Favorite

Optimal Two-Stage Randomized Multinomial Designs for Phase II Oncology Trials

By Sun Linda

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 485-493

Taylor & Francis Ltd

Access to resources Recommend Favorite

Ethical Issues in Including Pediatric Cancer Patients in Drug Development Trials

By Aleksa K.

Pediatric Drugs, Vol. 4, Iss. 4, 2002-01 ,pp. : 257-265

Adis International

Access to resources Recommend Favorite

Current and future directions for Phase II trials in high-grade glioma

By Alexander Brian M Lee Eudocia Q Reardon David A Wen Patrick Y

Expert Review of Neurotherapeutics, Vol. 13, Iss. 4, 2013-04 ,pp. : 369-387

Informa Healthcare

Access to resources Recommend Favorite

Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 8, Iss. 2, 2010-06 ,pp. : 146-166

Bentham Science Publishers

Access to resources Recommend Favorite